Akram, F; Wolf, J L; Trandafir, T E; Dingemans, Anne-Marie C; Stubbs, A P; von der Thüsen, J H (2023). Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies. Lung cancer, 186(107413), p. 107413. Elsevier 10.1016/j.lungcan.2023.107413
|
Text
1-s2.0-S0169500223009510-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (14MB) | Preview |
INTRODUCTION
Between 10 and 50% of early-stage lung adenocarcinoma patients experience local or distant recurrence. Histological parameters such as a solid or micropapillary growth pattern are well-described risk factors for recurrence. However, not every patient presenting with such a pattern will develop recurrence. Designing a model which can more accurately predict recurrence on small biopsy samples can aid the stratification of patients for surgery, (neo-)adjuvant therapy, and follow-up.
MATERIAL AND METHODS
In this study, a statistical model on biopsies fed with histological data from early and advanced-stage lung adenocarcinomas was developed to predict recurrence after surgical resection. Additionally, a convolutional neural network (CNN)-based artificial intelligence (AI) classification model, named AI-based Lung Adenocarcinoma Recurrence Predictor (AILARP), was trained to predict recurrence, with an ImageNet pre-trained EfficientNet that was fine-tuned on lung adenocarcinoma biopsies using transfer learning. Both models were validated using the same biopsy dataset to ensure that an accurate comparison was demonstrated.
RESULTS
The statistical model had an accuracy of 0.49 for all patients when using histology data only. The AI classification model yielded a test accuracy of 0.70 and 0.82 and an area under the curve (AUC) of 0.74 and 0.87 on patch-wise and patient-wise hematoxylin and eosin (H&E) stained whole slide images (WSIs), respectively.
CONCLUSION
AI classification outperformed the traditional clinical approach for recurrence prediction on biopsies by a fair margin. The AI classifier may stratify patients according to their recurrence risk, based only on small biopsies. This model warrants validation in a larger lung biopsy cohort.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology 04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Wolf, Janina Luisa |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
0169-5002 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
09 Nov 2023 12:48 |
Last Modified: |
11 Dec 2023 00:15 |
Publisher DOI: |
10.1016/j.lungcan.2023.107413 |
PubMed ID: |
37939498 |
Uncontrolled Keywords: |
Artificial intelligence Convolutional neural network Lung adenocarcinoma Recurrence prediction |
BORIS DOI: |
10.48350/188709 |
URI: |
https://boris.unibe.ch/id/eprint/188709 |